{"schema_version":"1.0","type":"article","title":"Why Are Lilly and Novartis Betting on How Medicines Are Delivered?","url":"https://drugnews.com.tw/articles/2026-09-24-delivery-platform-deals-lilly-kelonia-novartis-alteogen-2026-en.html","markdown_url":"https://drugnews.com.tw/articles/2026-09-24-delivery-platform-deals-lilly-kelonia-novartis-alteogen-2026-en.md","lang":"en","date":"2026-09-24","publish_at":"2026-09-24T08:00:00+08:00","updated_at":"2026-09-24","category":"商業分析系列","topic":"商業分析系列","tags":["藥物遞送","BD交易","細胞治療","in vivo CAR-T","皮下注射劑型","Eli Lilly","Kelonia","Novartis","Alteogen","平台型Biotech"],"summary":"Lilly's in vivo CAR-T acquisition and Novartis' subcutaneous formulation options address different delivery problems. Human evidence, drug exposure and payment terms clarify how each platform could create product value.","key_points":[],"facts":[],"sections":[],"references":[],"images":[{"alt":"Figure 1. The deals address cell-therapy manufacturing and biologic formulation, with different rights structures.","url":"https://drugnews.com.tw/assets/articles/delivery-platform-deals-lilly-kelonia-novartis-alteogen-2026-en/01_EN_branded.png"},{"alt":"Figure 2. In vivo CAR-T remains investigational. Intermediate molecular steps after vector entry are omitted.","url":"https://drugnews.com.tw/assets/articles/delivery-platform-deals-lilly-kelonia-novartis-alteogen-2026-en/02_EN_branded.png"},{"alt":"Figure 3. ALT-B4 temporarily breaks down subcutaneous hyaluronan to aid dispersion and absorption of a co-administered drug.","url":"https://drugnews.com.tw/assets/articles/delivery-platform-deals-lilly-kelonia-novartis-alteogen-2026-en/03_EN_branded.png"},{"alt":"Figure 4. Lilly's consideration comprises an upfront commitment and contingent milestones. Alteogen's individual amounts are undisclosed, with royalties additional.","url":"https://drugnews.com.tw/assets/articles/delivery-platform-deals-lilly-kelonia-novartis-alteogen-2026-en/04_EN_branded.png"}],"cover_image":"https://drugnews.com.tw/assets/articles/delivery-platform-deals-lilly-kelonia-novartis-alteogen-2026-en/01_EN_branded.png","publisher":{"name":"Drugnews｜藥時事","url":"https://drugnews.com.tw/","profile":"https://drugnews.com.tw/brand-profile.json"},"citation":"Drugnews｜藥時事（2026-09-24）。Why Are Lilly and Novartis Betting on How Medicines Are Delivered?。https://drugnews.com.tw/articles/2026-09-24-delivery-platform-deals-lilly-kelonia-novartis-alteogen-2026-en.html","disclaimer":"This article is intended for industry research and knowledge sharing only. It does not constitute investment, medical, fundraising, or individual stock advice.","translations":{"zh-Hant":"2026-09-24-delivery-platform-deals-lilly-kelonia-novartis-alteogen-2026.html"},"relationship":"independent_editorial","disclosure_url":"https://drugnews.com.tw/policy/"}